Drug Profile


Alternative Names: Olanedine; Olanexidine gluconate; OPB-2045; OPB-2045G

Latest Information Update: 10 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Otsuka Pharmaceutical
  • Class Antibacterials; Antifungals; Antiseptics; Biguanides; Small molecules
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Bacterial infections

Most Recent Events

  • 26 Jun 2017 Otsuka initiates enrolment in a phase II trial in Bacterial infections (Prevention, In infants, In adolescents, In children) in Japan (Topical) (UMIN000027899)
  • 16 Sep 2015 Launched for Bacterial infections (Prevention) in Japan (Topical)
  • 03 Jul 2015 Registered for Bacterial infections (Prevention) in Japan (Topical) - First global approval
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top